Morning, Thursday, 9th May 2019
THIS EVENT IS CPD CERTIFIED
This conference will be a timely opportunity to discuss the future for the regulation of medicines, clinical trials and medical devices in the UK - looking at patient safety, access and the next steps for policy.
Attendees will discuss what more could be done to ensure that the regulatory process supports the development of new treatments within the UK - in light of the expected launch of additional investment into a second phase of the Life Sciences Sector Deal.
Delegates will assess the changing landscape of healthcare regulation and the future role of the UK in European regulatory procedures - including key issues for maintaining access, innovation and the supply of medicines to the UK.
The seminar comes as MHRA prepares for different post-Brexit scenarios and as the European Medicines Agency (EMA) looks to relocate to Amsterdam by March 2019.
It also follows the Health and Social Care Commons Select Committee opening an inquiry into the impact of the Brexit withdrawal agreement on health and social care.
Attendees will also address the impact of the Early Access to Medicine Scheme, which aims to give patients access to medicines that do not yet have marketing authorisation - as well as next steps for working with patients in the decision making process.
Following the seizures of more than £2m of fake medicines and devices by the MHRA, and taking into account patient safety considerations, the agenda looks at what more could be done to deter the manufacture and supply of fake products in the future and also educate the public on safety advice when purchasing medicines.
Further sessions consider the future for regulation to ensure the transparency of clinical trials and maintain public trust, with the Science and Technology Commons Select Committee publishing its report into research integrity, which found that the non-publication of clinical trial results is a risk to human health.